Investors

A visible product.
A scalable platform opportunity.

Dr.AI is AI.EZER’s first product: a smart health checkpoint designed to bring accessible preventive screening into everyday institutions and public spaces.

Official Dr.AI Smart Health Checkpoint product artwork and feature overview

THE PRODUCT

Meet Dr.AI

A self-operated, non-contact health checkpoint that combines guided scanning, multi-modal sensing and AI-assisted reporting in one compact device.

  • Public-space deployment
  • Guided self-service
  • Non-contact workflow
  • Preventive health focus
  • Institutional dashboard pathway
  • Recurring platform revenue potential
See product, features & uses

Official product artwork; final specifications and health capabilities remain subject to validation.

01 / THESIS

Product, platform
and institutional scale.

Three complementary revenue paths create a focused entry and long-term platform upside.

REVENUE

Hardware + deployment

Diagnostic units, installation, calibration and maintenance.

REVENUE

Platform SaaS

Fleet dashboards, modules, updates and audit trails.

REVENUE

APIs + licensing

CRoS capabilities for device and solution partners.

REVENUE

Public-sector pilots

District programs, CSR partnerships and scale contracts.

18 moDeployment roadmap
2–3Target institutional pilots
EdgePrivacy + offline operation
IndiaSovereign deep-tech foundation

02 / WHY THIS PRODUCT

01

Clear customer need

Institutions need scalable preventive screening without adding specialist staff to every location.

02

Multiple deployment markets

Airports, employers, universities, clinics, hospitals, rural programmes and community centres.

03

Hardware + recurring revenue

Device deployment creates a path to software, reporting, support and fleet-management revenue.

04

Platform expansion

The AI.EZER cognitive platform can expand beyond healthcare into defence, space programmes, industry, agriculture, infrastructure and service robotics.

Request the investor brief.

For the current deck, technical diligence material and roadmap discussion.

Investor enquiry